OTCMKTS:SQZB SQZ Biotechnologies (SQZB) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free SQZB Stock Alerts $0.02 -0.03 (-57.92%) (As of 05/6/2024 05:40 PM ET) Add Compare Share Share Today's Range$0.02▼$0.0350-Day Range$0.02▼$0.0552-Week Range$0.01▼$0.65Volume16,641 shsAverage Volume180,334 shsMarket Capitalization$619,311.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsSEC FilingsShort Interest Get SQZ Biotechnologies alerts: Email Address Ad Stansberry ResearchControversial CEO explains new way to amass wealthThere's no shortage of controversial CEOs in America today... From Elon Musk... to Disney's Bob Iger... to JP Morgan's Jamie Dimon... But only one controversial CEO that I know of is willing to show you exactly how and why he cut his annual salary to $1...Don't miss Porter's brand-new presentation on this subject About SQZ BiotechnologiesSQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.Read More SQZB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SQZB Stock News HeadlinesFebruary 29, 2024 | businesswire.comSTEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies CompanyFebruary 29, 2024 | businesswire.comAsset Sale and Plan of Liquidation and Dissolution Approved by SQZB ShareholdersMay 7, 2024 | Stansberry Research (Ad)Do NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.December 12, 2023 | businesswire.comIntroducing Portal BiotechnologiesSee More Headlines Receive SQZB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/07/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:SQZB CUSIPN/A CIK1604477 Webwww.sqzbiotech.com Phone617-758-8672FaxN/AEmployees53Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,460,000.00 Net MarginsN/A Pretax Margin-591.07% Return on Equity-206.79% Return on Assets-99.55% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio1.37 Sales & Book Value Annual Sales$21.48 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.01Miscellaneous Outstanding Shares29,491,000Free Float24,772,000Market Cap$619,311.00 OptionableN/A Beta1.45 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Howard Bernstein M.D. (Age 67)Ph.D., Interim CEO & Director Comp: $552.14kMr. Lawrence J. Knopf Esq. (Age 62)General Counsel & Secretary Comp: $512.38kDr. Marshelle Smith Warren M.D. (Age 60)Chief Medical Officer Comp: $476.27kDr. Robert S. Langer Jr. (Age 75)Ph.D., Co-Founder & Member of Scientific Advisory Board Mr. Richard V. Capasso CPA (Age 62)Chief Accounting Officer Mr. David First (Age 60)Chief People Officer Ipsita Roymoulik Ph.D.Senior Vice President of CMC & QUALITYMore ExecutivesKey CompetitorsSQZ BiotechnologiesNYSE:SQZAcorda TherapeuticsNASDAQ:ACORQTC BiopharmNASDAQ:TCBPScinai ImmunotherapeuticsNASDAQ:SCNIAcorda TherapeuticsNASDAQ:ACORView All Competitors SQZB Stock Analysis - Frequently Asked Questions Should I buy or sell SQZ Biotechnologies stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SQZB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SQZB, but not buy additional shares or sell existing shares. View SQZB analyst ratings or view top-rated stocks. How have SQZB shares performed in 2024? SQZ Biotechnologies' stock was trading at $0.0199 at the beginning of 2024. Since then, SQZB shares have increased by 5.5% and is now trading at $0.0210. View the best growth stocks for 2024 here. Are investors shorting SQZ Biotechnologies? SQZ Biotechnologies saw a drop in short interest in March. As of March 31st, there was short interest totaling 27,700 shares, a drop of 38.4% from the March 15th total of 45,000 shares. Based on an average trading volume of 177,000 shares, the short-interest ratio is currently 0.2 days. View SQZ Biotechnologies' Short Interest. When is SQZ Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SQZB earnings forecast. How do I buy shares of SQZ Biotechnologies? Shares of SQZB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SQZB) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SQZ Biotechnologies Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
